Bookmarks
Randomised Evaluation of COVID-19 Therapy (RECOVERY)
Safe People
University of Oxford
Safe Projects
ILD67
The RECOVERY trial is evaluating the effectiveness of a number of potential treatments for COVID-19, including lopinavir-ritonavir, low-dose corticosteroids, hydroxychloroquine, azithromycin, convalescent plasma and tocilizumab.. UK Renal Registry data will be used to assess any effects of the treatments on the development of acute kidney injury and on the long-term risk of Chronic Kidney Disease and End Stage Kidney Failure following the initial acute illness. We would also wish to characterise our participants (eg, dialysis or transplant patients) at baseline using UK Renal Registry data. The trial will assess the efficacy and safety of the trial treatments in COVD-19 which will directly inform the care of millions of patients worldwide.
04/06/2020